CMS’s 2026 OPPS Rule and Hospital Survey Dilemma

If hospital leaders were hoping for a calm 2026, CMS had other ideas. The agency’s 2026 Hospital Outpatient Prospective Payment System rule arrived with a modest payment update, a bigger push toward site-neutral payment, major outpatient policy changes, and one especially prickly surprise: a drug acquisition cost survey that has hospitals wondering whether answering honestly could help cut their future reimbursement, while refusing to answer could create a different kind of trouble. In other words, the rule came bearing a calculator in one hand and a clipboard in the other.

That is why the real story of the 2026 OPPS rule is not just the headline payment number. It is the collision between reimbursement policy, 340B politics, administrative burden, and a survey process that many hospitals see as both consequential and maddeningly unclear. For finance teams, pharmacy departments, compliance officers, and executives, this is not a theoretical Washington debate. It is a live operational problem with real dollars attached.

What the 2026 OPPS rule actually does

A payment increase that looks better on paper than it feels in practice

At first glance, CMS’s 2026 OPPS rule offers a familiar kind of relief: hospitals that meet quality reporting requirements receive a 2.6% payment update. That figure is built from a 3.3% hospital market basket increase minus a 0.7 percentage-point productivity adjustment. On a spreadsheet, that sounds like a respectable little bump. In a hospital budget meeting, it can feel more like loose change found in the couch.

Why the cool reception? Because hospitals are navigating stubborn labor costs, pharmacy inflation, technology spending, regulatory compliance, and ongoing pressure to do more care in outpatient settings at lower margins. A 2.6% increase helps, but it does not magically erase the financial squeeze facing health systems, especially safety-net hospitals, rural hospitals, and organizations with heavy Medicare exposure.

The broader OPPS changes matter, too

The 2026 rule is not just a payment-rate update. CMS also finalized an expansion of site-neutral payment policy for drug administration services furnished in excepted off-campus provider-based departments. In plain English, CMS is trying to narrow the payment gap between hospital outpatient departments and physician office settings for certain services. Supporters call that rational. Hospitals tend to call it a cut wearing a reform nametag.

CMS also finalized a three-year phaseout of the inpatient-only list, starting with the removal of 285 mostly musculoskeletal procedures for 2026. At the same time, the agency added hundreds of procedures to the ambulatory surgical center covered procedures list. The message is clear: CMS wants more care delivered in lower-cost outpatient settings, and it is rewriting payment policy to make that happen.

Then there are the other notable provisions. CMS finalized new payment treatment for skin substitutes, continued temporary additional payments for certain non-opioid pain treatments, codified payment rules tied to domestically produced molybdenum-99, and pushed forward on hospital price transparency requirements. None of these policies exists in a vacuum. Together, they show an agency that is still leaning hard into cost discipline, data collection, and payment redesign.

Why the survey is the real drama

The rule’s quiet centerpiece is ODACS

The most politically charged piece of the 2026 OPPS rule is the OPPS Drug Acquisition Cost Survey, often called ODACS. CMS launched the survey on January 1, 2026, and later extended the submission deadline to April 7, 2026. The survey asks hospitals paid under OPPS to report drug acquisition cost data at the National Drug Code level for separately payable outpatient drugs purchased between July 1, 2024, and June 30, 2025.

This is not a light-touch questionnaire. Hospitals are expected to report total units purchased and total net acquisition costs, including discounts and rebates, for both 340B and non-340B purchases. CMS has signaled that the data will be used to inform policymaking beginning with the 2027 OPPS proposed rule. The agency has also said it will likely conduct this survey every four years, which means hospitals are not just dealing with a one-time nuisance. They may be staring at a recurring regulatory ritual.

CMS estimated that completing the survey would take about 80.5 hours per hospital, and that estimate has drawn more than a few raised eyebrows. In the real world, many hospitals see the lift as much larger, especially when pharmacy systems, purchasing systems, 340B split-billing tools, general ledger data, and outpatient charge structures do not line up neatly. If your organization likes tidy data, congratulations. If not, welcome to the party.

The 340B shadow hangs over everything

To understand why hospitals are so uneasy, you have to understand the 340B backstory. In 2022, the U.S. Supreme Court unanimously ruled that HHS had acted unlawfully when it reduced reimbursement rates for certain 340B hospitals without first conducting the kind of acquisition-cost survey contemplated by statute. That decision did not end the reimbursement fight. It simply changed the playbook.

Now CMS is running the survey that the earlier payment cuts lacked. That is why many hospitals, trade groups, and 340B advocates view ODACS as more than data gathering. They see it as the factual groundwork for future reimbursement cuts, potentially beginning in the 2027 OPPS cycle. That fear is especially acute for hospitals that depend on 340B savings to support oncology, infusion, pharmacy access, and care for patients with low incomes or complex needs.

Even hospital groups that are not reflexively opposed to data collection have warned that the survey is burdensome, strategically fraught, and potentially harmful if used to drive down payment rates without recognizing the real costs of running hospital outpatient services.

The hospital survey dilemma, in plain English

Answer the survey, and you may help write the rule that cuts you later

This is the first horn of the dilemma. If a hospital responds fully, it gives CMS richer data on its actual acquisition costs. That may strengthen the agency’s ability to argue that future reimbursement should be calibrated more closely to what hospitals actually pay for drugs. For some 340B hospitals in particular, that creates an uncomfortable question: are they being asked to help construct the record for a later reduction in Medicare drug payments?

That concern is not imaginary. Hospital groups, 340B advocates, and pharmacy stakeholders have repeatedly framed the survey as a likely precursor to future payment compression. From their perspective, participating may be prudent from a compliance and relationship standpoint, but it could also contribute to a reimbursement methodology that reduces revenue down the road.

Refuse to answer, and you may invite uncertainty anyway

The second horn is just as uncomfortable. CMS has acknowledged that the statute does not spell out specific consequences for failing to respond, yet agency materials have still told covered hospitals they are to participate. That wording triggered a pushback letter from a broad coalition of hospital associations, which argued that CMS was overstating the legal obligation and creating confusion.

Meanwhile, CMS has suggested that nonresponse could still be meaningful. In proposed-rule discussion, the agency floated the possibility that nonresponding hospitals might be treated as having lower acquisition costs than similar hospitals that did respond. That is the kind of sentence that makes lawyers reach for red pens and CFOs reach for antacids.

So hospitals face a nasty strategic choice. Participate, and potentially help inform future cuts. Decline, and risk CMS drawing inferences from silence or using imputed assumptions in later rate-setting. It is less a classic yes-or-no survey and more a choose-your-own-adventure written by actuaries.

Why hospitals say this is more than a paperwork issue

Hospital associations have not objected merely because the survey is annoying. Their argument is that the operational burden is serious and the policy implications are even bigger. Pulling accurate net acquisition cost data is difficult when purchasing channels differ across 340B, wholesaler acquisition cost accounts, and group purchasing arrangements. It gets harder when hospitals must separate outpatient from inpatient purchases or reconcile data across multiple sites, departments, and billing systems.

For 340B hospitals, the survey can also expose a mismatch between how drugs are purchased, how they are tracked, and how they are ultimately used. Some facilities have sophisticated split-billing systems and robust reporting. Others have patchier tools and more manual workarounds. That means the survey is not simply a data export. It can become a forensic accounting project involving pharmacy, finance, compliance, IT, and outside vendors.

There is also a fairness question. Hospitals argue that outpatient drug reimbursement cannot be evaluated in isolation from pharmacy overhead, uncompensated care, staffing, patient complexity, and the broader mission of hospital outpatient departments. A reimbursement formula built too narrowly around acquisition cost may look clean on paper while missing the messy economics of actual care delivery.

What smart hospitals are doing now

Building a cross-functional response team

The best-prepared hospitals are not letting ODACS sit in one lonely inbox. They are pulling together pharmacy leadership, revenue cycle, reimbursement analysts, 340B program managers, compliance, legal counsel, and IT support. That kind of team is necessary because the survey is part reimbursement exercise, part data governance exercise, and part strategic risk assessment.

Testing the data before submitting anything

Hospitals are also stress-testing their data before they send it. That means validating NDC mappings, confirming whether rebates and discounts are reflected properly, checking whether outpatient purchases are isolated accurately, and documenting assumptions. In a survey this sensitive, bad data can be worse than late data. At least lateness has the decency to be obvious.

Modeling the 2027 downside

Forward-looking organizations are also doing scenario planning. If CMS uses survey results to recalibrate payment rates in 2027, what could that mean for 340B drug reimbursement? How much exposure does the hospital have? Which service lines would feel the pinch first? A hospital that waits for the 2027 proposed rule to start modeling its risk is already behind.

What CMS is trying to do, and why the industry still resists it

To be fair, CMS is not acting irrationally. The agency wants payment policy to reflect market realities more closely, limit excess spending, and support a broader shift toward transparency and lower-cost settings of care. In that context, surveying hospitals on actual drug acquisition costs is not some bizarre bureaucratic hobby. It fits the administration’s larger payment and pricing agenda.

But hospitals believe CMS is underestimating two things. First, the operational burden of producing precise acquisition-cost data at scale is significant. Second, lowering payment closer to acquisition cost can ignore the wider structure of hospital outpatient care, especially in settings that serve medically complex patients or communities with fewer alternatives. If CMS sees the survey as a technical upgrade, hospitals see it as a strategic inflection point.

What the survey dilemma looks like inside a hospital: composite experiences from the field

Across the industry, the experience of the 2026 OPPS survey feels less like filling out a form and more like opening a nesting doll of administrative headaches. A pharmacy director may start with what sounds like a simple assignment: pull outpatient drug acquisition costs. Five minutes later, that “simple” task has turned into a scavenger hunt across wholesaler invoices, 340B split-billing software, charge masters, outpatient encounter data, and accounting records that do not all speak the same language.

In one common scenario, the revenue cycle team assumes pharmacy has the numbers. Pharmacy assumes finance has the rebate detail. Finance assumes the 340B vendor can distinguish outpatient and inpatient purchasing with a few clicks. Then everyone discovers that the data can be assembled, but not quickly, not elegantly, and definitely not without a lot of meetings that could have been emails if the universe were kinder.

Rural hospitals face a different version of the problem. They often have leaner staffing and less internal analytics capacity, so the burden of survey response falls on a handful of people already juggling contracting, audit prep, reimbursement issues, and day-to-day operations. For them, the dilemma is not abstract. It is practical: do we divert scarce staff time into a survey that may eventually support lower reimbursement?

Large academic medical centers, meanwhile, may have more resources but also far more complexity. Multi-site purchasing arrangements, mixed inventories, high-cost infused drugs, specialty pharmacy relationships, and complicated 340B patterns can make data extraction a small epic. These organizations may be more capable of answering CMS, but they also have more to lose if the survey leads to downward pressure on drug reimbursement across major outpatient service lines.

Essential hospitals and other safety-net institutions often describe the issue in mission terms. They do not just see drug reimbursement as a line item. They see it as fuel for oncology access, infusion capacity, pharmacy support, and community programs that might not otherwise pencil out. From that perspective, the survey can feel like being asked to hand over the blueprint to your own cost-cutting plan.

There is also a human factor that rule summaries often miss. Survey work tends to land on people who are already stretched thin and who rarely get credit for preventing a future mess. If the data are wrong, leadership notices. If the data are right, everyone moves on to the next fire drill. That makes ODACS the kind of assignment that quietly swallows time, attention, and goodwill inside organizations.

So when hospitals talk about the 2026 OPPS survey dilemma, they are not just talking about legal interpretation or reimbursement theory. They are talking about lived operational strain. They are talking about whether compliance effort today becomes financial pain tomorrow. And they are talking about making a strategic choice in a landscape where neither option feels especially comfortable.

Conclusion

CMS’s 2026 OPPS rule is a reminder that outpatient payment policy is no longer just about annual updates and technical tweaks. It is about how aggressively Medicare will push site-neutral logic, how much transparency it expects from hospitals, and how it intends to use data to reshape future reimbursement. The ODACS survey sits at the center of that story.

For hospitals, the dilemma is brutally simple and maddeningly complex at the same time. The simple part: the survey matters. The complex part: no one loves the options. Responding may support future payment changes that sting. Not responding may invite assumptions that sting differently. That is why the smartest organizations are treating the survey not as clerical cleanup but as a strategic event tied directly to 2027 reimbursement, 340B policy, and outpatient service planning.

In the end, the 2026 OPPS rule is not just asking hospitals how much they pay for drugs. It is asking how much uncertainty they can tolerate while CMS redraws the outpatient payment map. And that, unfortunately, is not a multiple-choice question.